The present disclosure provides a non-peripheral quaternary ammonium-modified zinc phthalocyanine and a preparation method and use thereof, belonging to the field of preparation of photodynamic drugs or photosensitizers. The non-peripheral quaternary ammonium-modified zinc phthalocyanine can be used as a photosensitizer for a photodynamic therapy (PDT) and photodynamic diagnosis, and can also be used for a photodynamic-immune synergistic therapy. Due to a unique structure, the non-peripheral quaternary ammonium-modified zinc phthalocyanine can be combined with an immune checkpoint blocker to achieve an excellent synergistic anti-tumor effect, which has a significant prospect for use in treating a metastatic tumor.

The present disclosure provides a non-peripheral quaternary ammonium-modified zinc phthalocyanine and a preparation method and use thereof, belonging to the field of preparation of photodynamic drugs or photosensitizers. The non-peripheral quaternary ammonium-modified zinc phthalocyanine can be used as a photosensitizer for a photodynamic therapy (PDT) and photodynamic diagnosis, and can also be used for a photodynamic-immune synergistic therapy. Due to a unique structure, the non-peripheral quaternary ammonium-modified zinc phthalocyanine can be combined with an immune checkpoint blocker to achieve an excellent synergistic anti-tumor effect, which has a significant prospect for use in treating a metastatic tumor.

The present application provides metallated porphyrin derivatives as ligands of G-quadruplex and their novel use as anti-viral agents. More specifically, this application is related to the use of porphyrin derivatives as G-quadruplex ligands to inhibit viral infections, such as HIV, more particularly to inhibit HIV-1 replication cycle.

The present application provides metallated porphyrin derivatives as ligands of G-quadruplex and their novel use as anti-viral agents. More specifically, this application is related to the use of porphyrin derivatives as G-quadruplex ligands to inhibit viral infections, such as HIV, more particularly to inhibit HIV-1 replication cycle.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of FGFR enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with FGFR signaling with the compounds and compositions of the disclosure.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of FGFR enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with FGFR signaling with the compounds and compositions of the disclosure.

A compound has, in a molecule, a cyclic structure represented by a formula (1) below; and at least one cyclic structure selected from the group consisting of a cyclic structure represented by a formula (10) below and a cyclic structure represented by a formula (11) below. In the formula (1): R.sub.1 to R.sub.16 are each independently a hydrogen atom, an alkyl group or the like; and R.sub.X and R.sub.Y are each independently an alkyl group.

##STR00001##

A compound has, in a molecule, a cyclic structure represented by a formula (1) below; and at least one cyclic structure selected from the group consisting of a cyclic structure represented by a formula (10) below and a cyclic structure represented by a formula (11) below. In the formula (1): R.sub.1 to R.sub.16 are each independently a hydrogen atom, an alkyl group or the like; and R.sub.X and R.sub.Y are each independently an alkyl group.

##STR00001##

The invention relates to heterocyclic compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.

A method for producing a halogenated zinc phthalocyanine pigment includes a step of forming a halogenated zinc phthalocyanine crude pigment into a pigment. The halogenated zinc phthalocyanine crude pigment is obtained by depositing a halogenated zinc phthalocyanine, which is synthesized by using a compound that generates an acid by reacting with water, and the aforementioned step includes a pretreatment step of dry-crushing the halogenated zinc phthalocyanine crude pigment by using an attritor and then washing the dry-crushed halogenated zinc phthalocyanine crude pigment with water.